Company profile ACRS

Aclaris Therapeutics Inc
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermat...ologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments. Show More
Quarter analysis & expected interest

There is not enough data for Aclaris Therapeutics, Inc. to provide analysis

Correlation between past revenue and Aclaris Therapeutics, Inc. search interest

There is not enough data for Aclaris Therapeutics, Inc. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aclaris Therapeutics, Inc. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aclaris Therapeutics drugs to provide analysis

Correlation between past revenue and Aclaris Therapeutics drugs search interest

There is not enough data for Aclaris Therapeutics drugs to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aclaris Therapeutics drugs to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aclaris Therapeutics treatments to provide analysis

Correlation between past revenue and Aclaris Therapeutics treatments search interest

There is not enough data for Aclaris Therapeutics treatments to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aclaris Therapeutics treatments to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aclaris Therapeutics research to provide analysis

Correlation between past revenue and Aclaris Therapeutics research search interest

There is not enough data for Aclaris Therapeutics research to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aclaris Therapeutics research to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aclaris Therapeutics Atopic Dermatitis to provide analysis

Correlation between past revenue and Aclaris Therapeutics Atopic Dermatitis search interest

There is not enough data for Aclaris Therapeutics Atopic Dermatitis to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aclaris Therapeutics Atopic Dermatitis to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aclaris Therapeutics Arthritis to provide analysis

Correlation between past revenue and Aclaris Therapeutics Arthritis search interest

There is not enough data for Aclaris Therapeutics Arthritis to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aclaris Therapeutics Arthritis to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aclaris Therapeutics cancer to provide analysis

Correlation between past revenue and Aclaris Therapeutics cancer search interest

There is not enough data for Aclaris Therapeutics cancer to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aclaris Therapeutics cancer to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 12:54:13.

After 39 days of this quarter the interest is at 298.0. Based on that we can calculate that during remaining 52 days it will total up to 695.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019357
502
40.6% QoQ
544
8.4% QoQ
436
-19.9% QoQ
2020 465
30.3% YoY 6.7% QoQ
450
-10.4% YoY -3.2% QoQ
475
-12.7% YoY 5.6% QoQ
390
-10.6% YoY -17.9% QoQ
2021 588
26.5% YoY 50.8% QoQ
508
12.9% YoY -13.6% QoQ
465
-2.1% YoY -8.5% QoQ
420
7.7% YoY -9.7% QoQ
2022 540
-8.2% YoY 28.6% QoQ
579
14.0% YoY 7.2% QoQ
619
33.1% YoY 6.9% QoQ
455
8.3% YoY -26.5% QoQ
2023 558
3.3% YoY 22.6% QoQ
584
0.9% YoY 4.7% QoQ
706
14.1% YoY 20.9% QoQ
681
49.7% YoY -3.5% QoQ
2024 298
-46.6% YoY -56.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ACRS -stock -company search interestLast update: February 08 2024 12:54:12.
Correlation coefficient between keyword and revenue is 0.37
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:54:13.

The average 5 years interest of ACRS -stock -company was 40.69 per week.
The last year interest of ACRS -stock -company compared to the last 5 years has changed by 22.51%.
The interest for ACRS -stock -company is trending.
The last year interest is quite higher compared to 5 years ago. It has increased by 27.56%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ACRS
Earnings date: 2024-02-22 After close
Company name: Aclaris Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-08T12:30:00Z

GlobeNewswire
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

2026-05-07T10:59:00Z

GlobeNewswire
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

2026-05-05T18:10:34Z

Analyst Upgrades
Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11

2026-05-05T12:45:27Z

Analyst Upgrades
Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12

2026-04-29T16:02:42Z

Analyst Upgrades
Wedbush Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $10

2026-04-28T10:30:00Z

GlobeNewswire
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

2026-04-27T20:45:00Z

GlobeNewswire
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

2026-04-16T12:19:48Z

Analyst Upgrades
Oppenheimer Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $10

2026-04-08T12:30:00Z

GlobeNewswire
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

2026-03-31T14:01:19Z

Analyst Upgrades
Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target

2026-03-27T14:10:00Z

GlobeNewswire
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

2026-03-19T12:12:35Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

2026-03-03T12:00:00Z

GlobeNewswire
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

2026-02-26T11:58:00Z

GlobeNewswire
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

2026-02-24T12:00:00Z

GlobeNewswire
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052